Dylan Fisher

In a pivotal trial, combination of nivolumab and ipilimumab yielded improvement in OS and ORR of poor-risk RCC patients.

The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy.

The US Food and Drug Administration has approved blinatumomab (Blincyto) for patients in remission from B-cell precursor ALL with MRD.